MARKET

RLAY

RLAY

Relay Therapeutics, Inc.
NASDAQ
14.42
+0.94
+6.97%
Opening 14:01 04/08 EDT
OPEN
14.00
PREV CLOSE
13.48
HIGH
14.49
LOW
13.84
VOLUME
1.81M
TURNOVER
--
52 WEEK HIGH
14.49
52 WEEK LOW
1.775
MARKET CAP
2.58B
P/E (TTM)
-8.9493
1D
5D
1M
3M
1Y
5Y
1D
Healthcare quant check: RLAY and TNGX lead Seeking Alpha’s top picks ahead of Q1 earnings
Seeking Alpha · 1d ago
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
NASDAQ · 2d ago
Weekly Report: what happened at RLAY last week (0330-0403)?
Weekly Report · 2d ago
Relay to present initial clinical data for zovegalisib in vascular anomalies at ISSVA 2026
Reuters · 5d ago
Relay Therapeutics To Present Initial Clinical Results, Preclinical Data For Zovegalisib In Vascular Anomalies At International Society For The Study Of Vascular Anomalies World Congress 2026
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 6d ago
Weekly Report: what happened at RLAY last week (0323-0327)?
Weekly Report · 03/30 09:58
Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/23 11:25
More
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Webull offers Relay Therapeutics Inc stock information, including NASDAQ: RLAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLAY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLAY stock methods without spending real money on the virtual paper trading platform.